Encoded Therapeutics is a biotechnology company developing genetic medicines for neurological disorders and other diseases. The company uses a genomics-driven platform to design precision gene therapies that regulate gene expression in specific cell types. Its technology combines regulatory element discovery, high-throughput genomic screening, computational modeling, and vector engineering to develop cell-selective therapies. Encoded’s lead program, ETX101, is a gene therapy candidate designed to modulate the SCN1A gene for the treatment of Dravet syndrome, a severe developmental and epileptic encephalopathy. The company also develops preclinical programs targeting other neurological disorders and explores applications in liver, metabolic, and cardiovascular diseases. Its genetic medicines product engine includes preclinical development, delivery optimization, GMP manufacturing, and clinical development capabilities. Encoded operates its own research and manufacturing infrastructure to support the development of its wholly owned therapeutic pipeline.